Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) has announced its participation in two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) has announced its participation in two virtual investor conferences. The Wells Fargo 2020 Virtual Healthcare Conference will be held on September 10 at 2:00 PM ET, followed by the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 4:10 PM ET. Live webcasts will be accessible on the company's website with replays available for two weeks. Sunesis focuses on developing targeted inhibitors for cancer, including SNS-510, currently in IND-enabling studies.
Details
News Market Reaction – SNSS
The recorded move for SNSS in the trading session of this news was +748.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences.
Wells Fargo 2020 Virtual Healthcare Conference
Date: Thursday, September 10
Time: 2:00 PM Eastern Time
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 21
Time: 4:10 PM Eastern Time
Live webcasts of the events will be available on the Sunesis website at http://ir.sunesis.com. A replay of each will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510. SNS-510 is in IND-enabling studies and vecabrutinib is completing a Phase 1b trial in patients with advanced B cell malignancies.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: | Par Hyare | |
| Maeve Conneighton | Sunesis Pharmaceuticals Inc. | |
| Argot Partners | 650-266-3784 | |
| 212-600-1902 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.